MCC950, a potent small-molecule inhibitor of NLRP3, has demonstrated significant efficacy in attenuating inflammatory responses across both preclinical studies and early-phase clinical trials, showing therapeutic potential for a range of diseases, including Alzheimer’s disease, type 2 diabetes mellitus, and cardiovascular disorders (Li et al., 2022). The gene discussed is NLRP3; the disease is diabetes mellitus.